{"doi":"10.1093/cid/ciac663","title":"Clinical, Virologic, and Immunologic Evaluation of Symptomatic Coronavirus Disease 2019 Rebound Following Nirmatrelvir/Ritonavir Treatment","abstract":"BACKGROUND: Nirmatrelvir/ritonavir, the first severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protease inhibitor, reduces the risk of hospitalization and death by coronavirus disease 2019 (COVID-19) but has been associated with symptomatic rebound after therapy completion. METHODS: Six individuals with relapse of COVID-19 symptoms after treatment with nirmatrelvir/ritonavir, 2 individuals with rebound symptoms without prior antiviral therapy and 7 patients with acute Omicron infection (controls) were studied. Soluble biomarkers and serum SARS-CoV-2 nucleocapsid protein were measured. Nasal swabs positive for SARS-CoV-2 underwent viral isolation and targeted viral sequencing. SARS-CoV-2 anti-spike, anti-receptor-binding domain, and anti-nucleocapsid antibodies were measured. Surrogate viral neutralization tests against wild-type and Omicron spike protein, as well as T-cell stimulation assays, were performed. RESULTS: High levels of SARS-CoV-2 anti-spike immunoglobulin G (IgG) antibodies were found in all participants. Anti-nucleocapsid IgG and Omicron-specific neutralizing antibodies increased in patients with rebound. Robust SARS-CoV-2-specific T-cell responses were observed, higher in rebound compared with early acute COVID-19 patients. Inflammatory markers mostly decreased during rebound. Two patients sampled longitudinally demonstrated an increase in activated cytokine-producing CD4+ T cells against viral proteins. No characteristic resistance mutations were identified. SARS-CoV-2 was isolated by culture from 1 of 8 rebound patients; Polybrene addition increased this to 5 of 8. CONCLUSIONS: Nirmatrelvir/ritonavir treatment does not impede adaptive immune responses to SARS-CoV-2. Clinical rebound corresponds to development of a robust antibody and T-cell immune response, arguing against a high risk of disease progression. The presence of infectious virus supports the need for isolation and assessment of longer treatment courses. CLINICAL TRIALS REGISTRATION: NCT04401436.","journal":"Clinical Infectious Diseases","year":2022,"id":238937,"datarank":2.9457521492853393,"base_score":3.970291913552122,"endowment":3.970291913552122,"self_citation_contribution":0.5955437870328184,"citation_network_contribution":2.350208362252521,"self_endowment_contribution":0.5955437870328184,"citer_contribution":2.350208362252521,"corpus_percentile":null,"corpus_rank":null,"citation_count":52,"citer_count":49,"citers_with_citation_signal":39,"citers_with_endowment":39,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9546,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT04401436"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2022-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":529097,"name":"Joseph M. Rocco","orcid":"0000-0003-4307-4934","position":1,"is_corresponding":false},{"id":564431,"name":"Kristin L. Boswell","orcid":"0000-0001-5264-3399","position":2,"is_corresponding":false},{"id":342096,"name":"Elizabeth Laidlaw","orcid":"0000-0001-8241-6859","position":3,"is_corresponding":false},{"id":727841,"name":"Frances Galindo","orcid":null,"position":4,"is_corresponding":false},{"id":830644,"name":"Anela Kellogg","orcid":null,"position":5,"is_corresponding":false},{"id":614939,"name":"Sanchita Das","orcid":"0009-0003-5429-928X","position":6,"is_corresponding":false},{"id":640096,"name":"Allison Roder","orcid":"0000-0002-7904-7244","position":7,"is_corresponding":false},{"id":294797,"name":"Elodie Ghedin","orcid":"0000-0002-1515-725X","position":8,"is_corresponding":false},{"id":863586,"name":"Allie Kreitman","orcid":"0000-0002-0390-5425","position":9,"is_corresponding":false},{"id":432708,"name":"Robin Dewar","orcid":"0000-0002-7840-3155","position":10,"is_corresponding":false},{"id":857370,"name":"Sophie Kelly","orcid":"0000-0001-8350-3671","position":11,"is_corresponding":false},{"id":342131,"name":"Heather Kalish","orcid":"0000-0002-4848-2067","position":12,"is_corresponding":false},{"id":653443,"name":"Tauseef Ur Rehman","orcid":"0000-0001-6939-8027","position":13,"is_corresponding":false},{"id":864124,"name":"Jeroen Highbarger","orcid":null,"position":14,"is_corresponding":false},{"id":399561,"name":"Adam Rupert","orcid":"0000-0002-3778-9856","position":15,"is_corresponding":false},{"id":551713,"name":"Gregory Kocher","orcid":"0000-0002-6866-2903","position":16,"is_corresponding":false},{"id":294669,"name":"Michael R. Holbrook","orcid":"0000-0002-0824-2667","position":17,"is_corresponding":false},{"id":332535,"name":"Andrea Lisco","orcid":"0000-0002-1475-356X","position":18,"is_corresponding":false},{"id":431963,"name":"Maura Manion","orcid":"0000-0003-0991-0011","position":19,"is_corresponding":false},{"id":290824,"name":"Richard A. Koup","orcid":"0000-0002-3090-7282","position":20,"is_corresponding":false},{"id":241760,"name":"Irini Sereti","orcid":"0000-0002-0076-0224","position":21,"is_corresponding":false},{"id":863585,"name":"Brian Epling","orcid":"0000-0002-7434-942X","position":0,"is_corresponding":true}],"reference_count":23,"raw_metadata":null,"created_at":"2026-07-19T00:22:31.741535Z","pmid":"36200701","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}